CD38 cílená léčba u mnohočetného myelomu

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F18%3AA1901YLP" target="_blank" >RIV/61988987:17110/18:A1901YLP - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00843989:_____/18:E0107284

Výsledek na webu

<a href="https://www.scopus.com/record/display.uri?eid=2-s2.0-85059230123&origin=resultslist&sort=plf-f&src=s&st1=CD38+targeted+treatment+for+multiple+myeloma&st2=&sid=21badbd68209ccb833aeda94a1f21306&sot=b&sdt=b&sl=78&s=TITLE-ABS-KEY%28CD38+targeted+treatment+fo" target="_blank" >https://www.scopus.com/record/display.uri?eid=2-s2.0-85059230123&origin=resultslist&sort=plf-f&src=s&st1=CD38+targeted+treatment+for+multiple+myeloma&st2=&sid=21badbd68209ccb833aeda94a1f21306&sot=b&sdt=b&sl=78&s=TITLE-ABS-KEY%28CD38+targeted+treatment+fo</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

čeština

Název v původním jazyce

CD38 cílená léčba u mnohočetného myelomu

Popis výsledku v původním jazyce

Souhrn CD 38 je univornmě a vysoce exprimován na plazmatických buňkách a stal se tak ideálním cílem pro léčbu mnohočetného myelomu (MM) pomocí anti-CD38 cílených monoklonálních protilátek (mAbs.)

Název v anglickém jazyce

CD38 targeted treatment for multiple myeloma

Popis výsledku anglicky

CD38 antigen is highly and uniformly expressed on plasma cells and thus represents an ideal target for the treatment of multiple myeloma (MM) with anti-CD38 monoclonal antibodies (mAbs). Daratumumab is the most advanced anti-CD38 mAb in the clinical development with approval in several indications, nevertheless isatuximab that targets completely different epitope of CD38 molecule is also very promising drug. Anti-CD38 possess pleiotropic mechanism of action that have been described also in other mAbs, but quite specific, novel and very important seems to be the immunomodulatory effect provided by depletion of several CD38+ immunosuppressive immune cell populations. CD38-targeted mAbs induce partial response or better in approximately 30 % of heavily pre-treated myeloma patients as monotherapy. Based on their favourable toxicity profile and distinct mechanism of action, anti-CD38 mAbs represents very attractive partner to back-bone anti-myeloma drugs. Indeed, daratumumab is already approved as a part of three distinct combination regimens in relapsed setting. The combination of daratumumab with lenalidomide and dexamethasone is considered to be the best treatment option in relapsed myeloma with unprecedented prolongation of median PFS, including high rate of good quality responses. CD38 targeted therapy is rapidly moving toward the first line treatment. Anti-CD38 mAbs have been also successfully tested in other plasma cell dyscrasias (such as AL amyloidosis), and they are examined in other hematological malignancies (such as CLL, ALL, AML, etc.) and even in solid oncology as well as in autoimmune disorders. Implementation of CD38 targeted mAbs have been significant milestone in the treatment of MM, similar to that of CD20 targeted mAbs in CLL or non-Hodgkin lymphomas. We believe that this drug may eventually help to reach the cure at least in a subset of MM patients in the near future. Key words: acute myeloid leukemia - CD38 - daratumumab - isatuximab - multiple myeloma.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Vnitřní lékařství

ISSN

0042-773X

e-ISSN

—

Svazek periodika

64

Číslo periodika v rámci svazku

10

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

10

Strana od-do

939-948

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-85059230123